Ratings by Cantor Fitzgerald (Prakhar Agrawal)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/17/2026 | Inventiva SA | IVA | New Coverage | Overweight (N/A) |
4.52 (4.62) |
2.21% | Details | |
| 6/25/2026 | Veradermics | MANE | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/24/2026 | Silence Therapeutics | SLN | New Coverage | Overweight (N/A) |
7.27 (10.50) |
44.43% | Details | |
| 5/22/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/27/2026 | Shattuck Labs, Inc. | STTK | New Coverage | Overweight (N/A) |
17.48 (7.53) |
-56.92% | Details | |
| 4/14/2026 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/31/2026 | Moonlake Immunotherapeutics | MLTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/30/2026 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/9/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2026 | Moonlake Immunotherapeutics | MLTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2026 | Veradermics | MANE | New Coverage | Overweight (N/A) |
42.91 (111.32) |
159.43% | Details | |
| 1/16/2026 | Arrowhead Pharma | ARWR | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2026 | Structure Therapeutics | GPCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/1/2025 | Evommune Inc | EVMN | New Coverage | Overweight (N/A) |
20.71 (12.14) |
-41.38% | Details | |
| 11/5/2025 | Madrigal Pharmaceuticals | MDGL | Upgrade | Overweight (Neutral) |
412.35 (553.48) |
34.23% | Details | |
| 10/22/2025 | Ardelyx, Inc | ARDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/15/2025 | Aclaris Therapeutis | ACRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/26/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/17/2025 | Metsera Inc | MTSR | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/17/2025 | Structure Therapeutics | GPCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Neutral (Overweight) |
6.03 (0.51) |
-91.54% | Details | |
| 9/12/2025 | aTyr Pharma | ATYR | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/10/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2025 | Structure Therapeutics | GPCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/22/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/15/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Overweight (N/A) |
8.95 (19.37) |
116.42% | Details | |
| 8/4/2025 | aTyr Pharma | ATYR | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/29/2025 | Metsera Inc | MTSR | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/25/2025 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/23/2025 | Structure Therapeutics | GPCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/18/2025 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/13/2025 | Metsera Inc | MTSR | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/29/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/29/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/27/2025 | Metsera Inc | MTSR | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/20/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/29/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/28/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2025 | aTyr Pharma | ATYR | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/21/2025 | aTyr Pharma | ATYR | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/4/2025 | Moonlake Immunotherapeutics | MLTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/3/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2025 | Aclaris Therapeutis | ACRS | New Coverage | Overweight (N/A) |
1.58 (5.68) |
259.49% | Details | |
| 3/14/2025 | aTyr Pharma | ATYR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2025 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2025 | Metsera Inc | MTSR | New Coverage | Overweight (N/A) |
29.81 (70.50) |
136.5% | Details | |
| 2/10/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/21/2025 | Keros Therapeutics | KROS | Downgrade | Neutral (Buy) |
10.86 (10.64) |
-2.03% | Details | |
| 1/10/2025 | Travere Therapeutics | TVTX | New Coverage | Overweight (N/A) |
19.00 (56.71) |
198.47% | Details | |
| 1/6/2025 | aTyr Pharma | ATYR | New Coverage | Overweight (N/A) |
3.98 (6.03) |
51.51% | Details | |
| 10/24/2024 | Keros Therapeutics | KROS | New Coverage | Overweight (N/A) |
57.99 (10.64) |
-81.65% | Details | |
| 6/28/2024 | Madrigal Pharmaceuticals | MDGL | New Coverage | Neutral (N/A) |
285.66 (412.35) |
44.35% | Details | |
| 4/9/2024 | Structure Therapeutics | GPCR | New Coverage | Overweight (N/A) |
44.41 (48.48) |
9.16% | Details | |
| 3/4/2024 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | ORIC Pharamceuticals | ORIC | New Coverage | Overweight (N/A) |
10.12 (10.73) |
6.03% | Details | |
| 2/20/2024 | Rapt Therapeutics | RAPT | Downgrade | Neutral (Overweight) |
25.97 (58.02) |
123.41% | Details | |
| 10/10/2023 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/19/2023 | Akero Therapeutics | AKRO | New Coverage | Overweight (N/A) |
52.25 (54.74) |
4.77% | Details | |
| 9/19/2023 | Akero Therapeutics | AKRO | New Coverage | Overweight (N/A) |
52.25 (54.74) |
4.77% | Details | |
| 7/3/2023 | Moonlake Immunotherapeutics | MLTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/20/2023 | DICE Therapeutics | DICE | Downgrade | Neutral (Overweight) |
33.85 (47.55) |
40.47% | Details | |
| 3/14/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Provention Bio Inc. | PRVB | Downgrade | Neutral (Buy) |
6.70 (24.98) |
272.84% | Details | |
| 2/14/2023 | Moonlake Immunotherapeutics | MLTX | New Coverage | Overweight (N/A) |
16.30 (19.68) |
20.74% | Details | |
| 2/7/2023 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/25/2023 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2023 | Alaunos Therapeutics Inc. | TCRT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2022 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/28/2022 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2022 | DICE Therapeutics | DICE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/14/2022 | DICE Therapeutics | DICE | New Coverage | Overweight (N/A) |
18.50 (33.85) |
82.97% | Details | |
| 9/6/2022 | Alaunos Therapeutics Inc. | TCRT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/1/2022 | Forma Therapeutics | FMTX | Downgrade | Neutral (Overweight) |
13.40 (20.01) |
49.33% | Details | |
| 7/15/2022 | Alaunos Therapeutics Inc. | TCRT | New Coverage | Overweight (N/A) |
1.40 (2.05) |
46.43% | Details | |
| 6/13/2022 | Forma Therapeutics | FMTX | New Coverage | Overweight (N/A) |
5.61 (20.01) |
256.68% | Details | |
| 5/24/2022 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
12.56 (25.97) |
106.77% | Details |
